T 0601/05 (Anti-TNF alpha human monoclonal antibodies/BAYER III) of 02.12.2009
- European Case Law Identifier
- ECLI:EP:BA:2009:T060105.20091202
- Date of decision
- 2 December 2009
- Case number
- T 0601/05
- Petition for review of
- -
- Application number
- 94102560.3
- IPC class
- C07K 16/24
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- T 0601/05 Anti-TNF alpha human monoclonal antibodies/BAYER I 2007-10-18T 0601/05 Anti-TNF alpha human monoclonal antibodies/BAYER II 2008-04-24
- Abstracts for this decision
- -
- Application title
- Anti-TNF alpha human monoclonal antibodies
- Applicant name
- Bayer Corporation
- Opponent name
- Centocor, Inc.
Abbott Laboratories - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(1)European Patent Convention Art 114(2)European Patent Convention Art 116European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 57European Patent Convention Art 83European Patent Convention Art 84
- Keywords
- Admission of late-filed documents - (partly)
Admission of late-filed auxiliary requests 1 to 3 - (no)
Main request - sufficiency of disclosure - (no)
Auxiliary request 4 - added matter, extension of scope (no); clarity and support (yes); sufficiency of disclosure, novelty, inventive step (yes)
Right to be heard violated by (i) non-admission of parts of documents and (ii) limitation of time to speak at oral proceedings (no) - Catchword
- see points 11 to 17, 21 to 44 and 121 to 126
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the department of first instance with the order to maintain the patent on the basis of the following documents:
Claims: 1 to 4 of auxiliary request 4 filed at the oral proceedings.
Description: page 3 filed at the oral proceedings;
pages 4 to 18 of the patent specification.
Figures: 1 to 12 of the patent specification.